These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 34435696)

  • 1. The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first-line therapy for patients with metastatic castration-resistant prostate cancer.
    Wang Z; Zhu S; Zhao J; Nie L; Chen X; Zhang M; Chen N; Sun G; Chen J; Ni Y; Dai J; Liu Z; Tao R; Zhang X; Zhu X; Zhang H; Liang J; Wang Z; He B; Shen P; Zeng H
    Prostate; 2021 Nov; 81(15):1191-1201. PubMed ID: 34435696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroendocrine differentiation predicts the therapeutic efficacy of abiraterone and docetaxel as first-line therapy in metastatic castration-resistant prostate cancer.
    Xu N; Zhao J; Zhao F; Liu H; Yin W; Zhu S; Nie L; Sun G; Zheng L; Liu Z; Cai D; Chen J; Dai J; Ni Y; Wang Z; Zhang X; Liang J; Chen Y; Hu X; Pan X; Yin X; Zhu X; Zhang Y; Wang Z; Zeng Y; Wang M; Shen P; Chen N; Zeng H
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7247-7258. PubMed ID: 36907910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic implication of intraductal carcinoma of the prostate in metastatic castration-resistant prostate cancer and its potential predictive value in those treated with docetaxel or abiraterone as first-line therapy.
    Zhao J; Shen P; Sun G; Chen N; Liu J; Tang X; Huang R; Cai D; Gong J; Zhang X; Chen Z; Li X; Wei Q; Zhang P; Liu Z; Liu J; Zeng H
    Oncotarget; 2017 Aug; 8(33):55374-55383. PubMed ID: 28903426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapy.
    Zhao J; Zhang M; Liu J; Liu Z; Shen P; Nie L; Guo W; Cai D; Liu J; Armstrong CM; Sun G; Chen J; Zhu S; Dai J; Zhang H; Zhao P; Zhang X; Yin X; Zhu X; Ni Y; Chen N; Zeng H
    Prostate; 2019 Sep; 79(13):1553-1562. PubMed ID: 31294486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients.
    Fan L; Wang R; Chi C; Cai W; Zhang Y; Qian H; Shao X; Wang Y; Xu F; Pan J; Zhu Y; Shangguan X; Zhou L; Dong B; Xue W
    Prostate; 2018 Mar; 78(4):250-256. PubMed ID: 29285775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer.
    Azad AA; Leibowitz-Amit R; Eigl BJ; Lester R; Wells JC; Murray RN; Kollmannsberger C; Heng DY; Joshua AM; Chi KN
    Prostate; 2014 Nov; 74(15):1544-50. PubMed ID: 25175831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer.
    Schweizer MT; Zhou XC; Wang H; Bassi S; Carducci MA; Eisenberger MA; Antonarakis ES
    Eur Urol; 2014 Oct; 66(4):646-52. PubMed ID: 24491307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting abiraterone efficacy in advanced prostate cancer: Insights from marker of proliferation Ki67.
    Zhao F; Zhao J; Wei X; Shi Y; Xu N; Zhu S; Chen J; Sun G; Dai J; Wang Z; Zhang X; Liang J; Hu X; Liu H; Zhao J; Liu Z; Nie L; Shen P; Chen N; Zeng H
    Prostate; 2024 Jul; 84(10):932-944. PubMed ID: 38629249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
    Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
    JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and toxicity of abiraterone and docetaxel in octogenarians with metastatic castration-resistant prostate cancer.
    Leibowitz-Amit R; Templeton AJ; Alibhai SM; Knox JJ; Sridhar SS; Tannock IF; Joshua AM
    J Geriatr Oncol; 2015 Jan; 6(1):23-8. PubMed ID: 25301537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical activity of abiraterone plus prednisone in docetaxel-naοve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer.
    Lin GW; Li GX; Dai B; Ye DW; Kong YY; Wang Y; Shen YJ
    Asian J Androl; 2019; 21(2):131-136. PubMed ID: 30560837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone.
    Suzman DL; Luber B; Schweizer MT; Nadal R; Antonarakis ES
    Prostate; 2014 Sep; 74(13):1278-85. PubMed ID: 25053178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic role of early PSA drop in castration resistant prostate cancer patients treated with abiraterone acetate or enzalutamide.
    Buttigliero C; Tucci M; Sonetto C; Vignani F; Di Stefano RF; Pisano C; Turco F; Lacidogna G; Guglielmini P; Numico G; Scagliotti GV; Di Maio M
    Minerva Urol Nefrol; 2020 Dec; 72(6):737-745. PubMed ID: 32284527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
    Maughan BL; Xhou XC; Suzman DL; Nadal R; Bassi S; Schweizer MT; Antonarakis ES
    Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular features and race-associated outcomes of SPOP-mutant metastatic castration-resistant prostate cancer.
    Stangl A; Wilner C; Li P; Maahs L; Hwang C; Pilling A
    Prostate; 2023 May; 83(6):524-533. PubMed ID: 36604824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.
    Ueda Y; Matsubara N; Takizawa I; Nishiyama T; Tabata K; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H
    Jpn J Clin Oncol; 2015 Aug; 45(8):774-9. PubMed ID: 25981621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis.
    Brasso K; Thomsen FB; Schrader AJ; Schmid SC; Lorente D; Retz M; Merseburger AS; von Klot CA; Boegemann M; de Bono J
    Eur Urol; 2015 Aug; 68(2):317-24. PubMed ID: 25108579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.
    Seitz AK; Thoene S; Bietenbeck A; Nawroth R; Tauber R; Thalgott M; Schmid S; Secci R; Retz M; Gschwend JE; Ruland J; Winter C; Heck MM
    Eur Urol; 2017 Nov; 72(5):828-834. PubMed ID: 28818355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Third-line Enzalutamide Following Docetaxel and Abiraterone in Metastatic Castrate-resistant Prostate Cancer.
    Davies RS; Smith C; Lester JF
    Anticancer Res; 2016 Apr; 36(4):1799-803. PubMed ID: 27069162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abiraterone Acetate and Enzalutamide: Similar Efficacy in Treating Post Docetaxel Metastatic Castration-resistant Prostate Cancer: Single Center Experience.
    Chang LW; Hung SC; Wang SS; Li JR; Yang CK; Chen CS; Ho HC; Cheng CL; Ou YC; Chiu KY
    Anticancer Res; 2019 Jul; 39(7):3901-3908. PubMed ID: 31262919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.